Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.

Roberto Cauda, Jm Molina, M Ait Khaled, R Rinaldi, G Penco, Jg Baril, V Soriano, G Pialoux, Mb Wire, Y Lou, N Given, C Craig, Wg Nichols, I Barbosa, J. Yeo

Risultato della ricerca: Contributo in rivistaArticolo in rivista

6 Citazioni (Scopus)

Fingerprint

Entra nei temi di ricerca di 'Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.'. Insieme formano una fingerprint unica.

Medicine & Life Sciences